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An incidence of betw-een 2 and 44 per 1000 population has been reported for community-acquired pneumonia, 
Epidemiologic studies describe a wide range of causative organisms, including Streptococcus pneumoniae, 
Haemophilus influenzae, Mycoplasma pneumoniae, Legionella spp., Moraxella catarrhalis, Chlamydia pneumoniae and 
viruses such as influenza A and B. However, the frequency with which they are reported varies widely. On analysis of 
these studies, the variation can be explained by a number of factors. The results depend on the definition of pneumonia 
and the criteria for assigning a causative role to any particular organism. Older studies have not included diagnostic 
methods for newly described organisms such as C. pneumoniae and Legionella spp. The improved diagnostic methods 
for these organisms and for Mycoplasma pneumoniae are reflected in more recent studies. Further variation depends 
on the population studied. As many patients with mild pneumonia are successfully treated in the community, those 
studies that are hospital-based include patients with more severe pneumonia often in the elderly or in patients with 
underlying diseases such as chronic obstructive pulmonary disease. The prior use of antibiotics not only contributes to 
the high percentage of cases for which no etiologic agent is found, but also ensures that treatment failures are selected 
for hospitalization. This further changes the result, depending on the antibiotic agents used most commonly in the 
community. The inclusion of nursing home patients or groups where alcoholism is more common will also favor 
particular organisms. Finally, the timing of the study may be such that an epidemic is included. This has relevance mostly 
for Mycoplasma pneumoniae, C. pneumoniae, Legionella spp. and influenza. 
In the assessment of the patient with community-acquired pneumonia, any one of the above organisms can be 
considered to be responsible. As initial treatment is empirical, other information can be used to ensure that an antibiotic 
with an adequate spectrum is chosen. Factors of importance are age, underlying illness, severity of disease and any 
locally recognized epidemics or endemic organisms. Differences in clinical presentation are not sufficiently distinct to 
allow for accurate prediction of the causative agent. Similarly, chest radiograph changes are not sufficiently specific to 
discriminate reliably between diverse organisms such as S. pneumoniae, Mycoplasma pneumoniae and Legionella spp. 
Current recommendations for choice of an empirical antibiotic agent are therefore based, not on the assumption of a 
single etiologic agent indicated by clinical presentation or radiographic appearances, but on age of the patient, severity 
of illness, the presence of underlying conditions and the range of possible organisms in that patient group. 
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Community-acquired pneumonia (CAP) is a poten- 
tially serious infection that results in numerous general 
practitioner visits and hospital admissions each year, and 
accounts for a considerable amount of antibiotic 
prescribing. The mortality rate, particularly for the 
elderly, has been increasing since the early 1980s despite 
the use of an ever-increasing range of broad-spectrum 
antibiotics, and the availability and use of more 
sophisticated investigations and advances in supportive 
care [l]. The incidence of CAP has been reported in a 
number of studies as being 2.6 [Z], 4.7 [3], 10 [4], and 
44 [5] cases per 1000 population. This wide variation 
is due in part to the definition of CAP, with the lower 
rates occurring when both clinical and radiologic 
evidence of pneumonia are required for the diagnosis, 
and in part to the occurrence of epidemics during the 
study period. 
EPIDEMIOLOGY OF COMMUNITY-ACQUIRED 
PNEUMONIA 
There have been many epidemiologic studies, in both 
hospital and community populations, to determine the 
organisms responsible for CAP Tables 1 to 4 outline a 
number of these studies [3-131. These are by no means 
all of the studies that have been performed, but they 
have been chosen for comparison because of the size of 
the study population, the length of time over which the 
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Table 1 Community studies: summary of some of the features of the community-based CAP studies discussed in the text 
Etiology Prior 
Study Ref. Country N Average age Mortality (“h) established (‘Yo) antibiotics 
Wctodhead et a1 [31 UK 236 59 3 55 17 
MacFarlane et a1 [41 UK 206 NS 0 44 0 
Almirall et a1 151 Spain 105 48 1 44 62 
NS = not specified. 
Table 2 Community studies: the frequency with which various organisms were isolated from patients in the different 
community-based studies 
S. H .  Moraxella Mycoplasma kgionella Chlamydia Other 
Study Ref. pneumoniae inzuenzae catarrhalis pneumoniae spp. pneumoniae organisms 
Woodhead et a1 PI 36 10 0 1 0.5 NT 18 
MacFarlane et a1 [41 30 8 2 0.5 0 0 14 
Alniirall et a1 151 12 0 0 8 3 15 13 
NT = not tested. 
Table 3 Hospital studies: summary of some of the feature5 of the hospital-based CAP studm discussed in the text 
Average Etiology Prior antibiotics 
Study Ref. Country N age Mortality (“h) established (“A)) (“A,) 
Fang et a1 [71 USA 359 62 14 58 21 
Ortqvist et a1 PI Sweden 277 62 4 68 32 
Blanquer et a1 191 Spain 510 58 6 55 0 
Bates et a1 11 01 USA 154 64 25 50 28 
Ostergaard et a1 [I11 Denmark 254 65 6 34 32 
Blasi et a1 [I21 Italy 108 51 NS 54 62 
Mdrrie et a1 [61 Canada 719 63 21 (40) a 50 32 
Christiansen et a1 ~ 3 1  Australia 265 56 11 33 41 
”Figures in parcritheses denote iiiortality in nursing home patients 
NS = not specified. 
Table 4 Hospital studes: the frequency with which various organisms were isolated from patients in the different hospital- 
bated studies (%) 
Study 
S. H.  Moraxella Mycoplasma Chlamydia Other 
Ref. pneumonia? infuenzae catarrhalis yneumoniae LeAionella spp. pnrnmoniae organisms 
Marrie et a1 [61 8.5 4 0.3 5.6 2 3 35 
Fang et a1 [71 15 11 NS 2 7 6 18 
Ortqvist et a1 PI 46 4 3 10 4 0 21 
Ulanquer et a1 “,I 14 4 NS 4 14 NT 21 
Ostergaard et a1 [I11 14 6 1 4 3 1 12 
Blasi et al [I21 9 NS NS 14 3 13 10 
Christiansen et a1 1131 10 7 1 4 3 2 12 
Bates et a1 [I01 6 1 NS 3 9 8 23 
NS = not specified. N T  = not tested. 
study was conducted, and the use of a representative 
number ofdiagnostic tests, and because ofhaving been 
carried out  within the last 10 years. Also included are 
data collected in  a prospective study at the Royal Perth 
Hospital in  Western Australia on all patients admitted 
to  this teaching hospital over a 1-year period [l2]. In 
Tables 2 and 4 the bacteria listed are those that were 
isolated with the greatest frequency. Non-bacterial 
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causes (viruses and fungi) and bacteria of lower fre- 
quency, e.g. Gram-negative bacilli and Coxiella bumetii, 
are included under ‘other organisms’. Although the 
range of reported organisms, such as Streptococcus pneu- 
moniae, Haemophilus injuenzae, Mycoplasma pneumoniae, 
Legionella spp, Moraxella catarrhalis, Chlamydia pneu- 
moniae and viruses such as influenza A and B, is 
comparable, their frequency varies widely. Why is this 
so? Do the causes of pneumonia vary so much between 
countries and indeed within the same country? The 
answer is probably ‘no’, and the explanation for the 
variation lies in the way in which the study was 
conducted, thus making comparisons difficult. The 
variables are numerous and it is worthwhile looking at 
them in some detail. 
Definition of pneumonia 
The definition of pneumonia is poorly standardized 
between the studies listed in Tables 1 and 3. Most 
definitions have the requirement for both clinical 
symptoms and signs and new or progressive radio- 
graphic changes consistent with pneumonia, but the 
acceptable clinical signs vary widely. Also, obtaining the 
necessary clinical features may be difficult in the elderly, 
who do not always mount a febrile response or a raised 
white blood cell count. Two of the community-based 
studies rely on the clinical presentation alone [3,4] there 
being no requirements for radiographic changes. Thus 
potentially these studies may include patients with acute 
exacerbations of chronic bronchitis or viral bronchitis. 
When was the study conducted? 
The older studies did not have the advantage of the 
sophisticated investigation techniques available to the 
more recent investigators. Techniques such as induced 
sputum collection, transtracheal aspiration (TTA) and 
closed-brush bronchoscopy are examples. The use of 
TTA was central to the study by Ostergaard and 
Andersen Ill], in which a causative role for an 
organism was ascribed only if obtained by either TTA 
(performed on 47% of patients, with positive results in 
55%), a positive blood culture or positive serology. 
Closed-brush bronchoscopy was performed on 31% of 
patients in the study by Bates et a1 [lo], yielding a 
positive result in 38%. Also, there has been the 
recognition of new organisms, such as the non- 
pneumophila species of Legionella and C. pneumoniae, 
and the pathogenic potential has been realized for what 
were once only considered oral flora, e.g. Moraxella 
catarrhalis. Antigen-detection techniques, culture 
methods and serologic tests have improved over the last 
10 years, although not all these advances have been 
employed by the chosen studies, with some of these 
organisms not being tested or reported. 
Community- or hospital-based studies? 
The tables have been divided into those studies that are 
community-based (Tables 1 and 2) and those con- 
ducted on hospitalized patients (Tables 3 and 4). There 
were very few of the former from which to choose, in 
contrast to the many studies on patients admitted to 
hospital. The study populations in these two groups 
differ significantly. The hospital studies are based on 
patients with more severe pneumonia, the elderly and 
patients with concurrent medical problems, whereas 
many younger patients are successfully treated in the 
community Blanquer et a1 [9] showed that in the 9% 
of patients who were treated as outpatients compared 
to those hospitalized, the mean age was lower (41 versus 
60 years) and there was a significant difference in the 
percentage of patients with Mycoplasma pneumoniae 
(12.5% versus 3.5%). Thus, it is probable that Myco- 
plasma pneumoniae is found more commonly in non- 
hospitalized patients, but in some of the community 
studies the sophisticated laboratory techniques required 
to optimize the detection of these organisms have not 
been employed. Using only the data from hospital 
studies can be misleading, particularly if applied to 
patients managed within the community. 
Inclusion or exclusion of patients from nursing homes 
Most of the studies do not specify whether nursing 
home admissions are included. Two [5,10) specified 
their inclusion, with Marrie et a1 [6] giving a separate 
analysis of results for this patient population. In the 
nursing home group the mortality rate was higher, 
fewer patients had positive cultures or an identifiable 
cause for the pneumonia, many of the clinical signs 
associated with pneumonia were absent and there were 
fewer cases of Mycoplasnza pneumoniae infection but an 
increase in aspiration pneumonia. It can be argued 
equally that these patients should be included or 
excluded. However, as either stance will shift the age 
distribution of the study population and change the 
spectrum of infecting organisms, results should be 
presented separately. 
Prior use of antibiotics 
In all but two of the studies listed in Tables 1 to 4 
antibiotics had been given to some of the study 
population. This can influence the data in several ways. 
First, the isolation rate for pathogens could be expected 
to be decreased, particularly for very susceptible S. 
pneumoniae. Second, the type of antibiotics commonly 
used in the community will influence the pathogens 
most likely to be seen with treatment failure. For 
example, if p-lactanis are used, patients failing therapy, 
and hence requiring admission to hospital, are more 
likely to have Mycopfarma, Chlamydia or Legionella 
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infections. Conversely, if macrolides or tetracyclines are 
in common usage, the failures are more likely to be due 
to S. pneumoniac or H .  influenzae, depending on local 
susceptibility profiles. Blasi et a1 [12], who reported a 
high isolation rate for both Mycoplasma and Chlamydia 
in hospitalized patients, commented on the pre- 
dominant use of p-lactani antibiotics by Italian general 
practitioners. 
Type of hospital 
The population varies between hospitals, with some 
having a predominance of elderly patients, patients 
from disadvantaged socio-economic groups or patients 
with alcohol problems. In the study by Fang et al (71, 
three different hospitals were included. One of these, a 
veterans’ hospital, had a significantly higher incidence 
of excessive alcohol intake, cigarette smoking and 
presence of chronic obstructive pulnionary disease 
when compared to the other two hospitals. Although 
in this study there was no difference in the microbial 
etiology of pneumonia between the three facilities, 
selection for particular pathogens in these patient 
subgroups is possible. 
local factors 
The occurrence of an epidemic of Legtonella, Chlamydia 
or Mycoplasma during the study period can nusrepresent 
the frequency of these organisms when compared with 
the non-epidemic intervals. Some studies also reflect 
the prescnce of an endemic organi5m that may not be 
encountered by other workers; for exaniple, Marrie et 
a1 16) reported an incidence of 4% for Cowella brirnetii 
Age distribution of the study population 
This has been discussed in relationship to the inclusion 
of nursing home patients and to the differences between 
hospitalized and community patients. In addition, for 
thc community studies, the median age of the study 
population may bc lowered by the presence of large 
educational institutions or raised by a disproportionate 
number of retired residents. 
Criteria for inclusion of organisms 
Use of microscopy and culture of sputum 
Sputum is one of the most controversial specimens used 
in epidemiologic studies. As many of the pathogens 
in the respiratory tract are also conimensals in the 
oropharynx, the isolation of an organism from sputum 
docs not necessarily implicate it as the causative 
organism. The studies cited have dealt with this in a 
variety ofways. Some have completely rejected sputum 
as a means of identif;iing a pathogen [5,10,11]. Others 
have subdivided the likelihood of pathogenicity on 
factors such as presence of the organism on Gram stain, 
the organisms being present in  predominant numbers 
in a well-collected specimen (few epithelial cells, many 
leukocytes)[6,7,13] or the use of a semiquantitative 
culture technique [4,8,9,12]. Even using the latter 
method, the criterion differs, with 10’ CFU/mL being 
accepted by Ortqvist et a1 181 and 107CFU/mL by Blasi 
et a1 LIZ]. Isolation of Legionella, Myroplasma or 
Chlamydia was considered significant from any respira- 
tory specimen for those studies in which the relevant 
culture techniques were employed. 
Use of antigen-detection techniques 
The studies reporting the highest incidence of S. 
pneumoniae (Ortqvist et a1 [S] 46%, Woodhead et a1 131 
36%, MacFarlane et a1 [4] 30%) employed the use of 
S. pneumoniae polysaccharide capsular antigen detection 
in sputum and urine in addition to sputum culture. A 
positive antigen result was considered sufficient to 
ascribe a causative role for that organism. Two other 
studies also employing this technique (Blanquer et a1 [Y] 
14%, Almirall et a1 [5] 12%) had much lower rates, 
which approximate the results from remaining studies. 
The reason for this marked difference is not apparent, 
although Almirall et a1 151 did not include sputum 
culture in the diagnostic work-up. The sensitivity of 
pneumococcal antigen detection is high but the 
specificity is difficult to determine. Are some of these 
antigen positives due to lower respiratory tract coloniza- 
tion i n  patients with chronic obstructive pulmonary 
disease or to oral colonization in others? This question 
has yet to be resolved. 
Other antigen-detection techniques variably eni- 
ployed were direct Lcgionella immunofluorescence 
detection on respiratory tract specimens or Legiorzella 
antigen detection in urine. One  study [ l2]  used an  
indirect immunofluorescent C. pncuurrorziac~ antigen test 
on pharyngeal specinlens in addition to specific 
serology. 
Use of specialized culture techniques 
Six of the 11 reported studies employed respiratory 
specimen culture, four of which also used direct 
imniunofluorescence antigen detection, for Lqionella. 
The reported incidence of Legionella infection parallels 
this. The community studies. none of which used 
culture, reported 096, 0.5% and 3% of pneumonia due 
to Legionella based solely on serology. In the hospital 
studies, the incidence, in general, was higher for those 
that used culture and direct imniunofluoresccnce: 
Blanquer et a1 191 (14%), Bates et al [lo] (%), Fang et 
a1 [7] (7%), Christiansen et a1 [ 131 (3%). C. pneumoniae 
culture was not attempted by any of the investigators. 
With the recognition that the HE1’2 and H2Y2 cell 
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lines are more efficient for the propagation of this 
organism, future studies may be able to avoid many of 
the problems inherent in relying on serology for a 
diagnosis of infection with this organism [14]. 
Serologic investigations 
There are a number of variables in the serologic 
screening used in the various studies. The range of tests 
performed is fairly standard, with serology for influenza 
A and B and other respiratory viruses, Mycoplasma pneu- 
moniae, Coxiella bumetii, Chlamydia spp. and Legionella 
spp. being done. The three organisms for which par- 
ticular problems can be identified are C. pneumoniae, 
Mycoplasma pneumoniae and Legionella spp. 
Chlamydia pneumoniae 
The two methods employed for the detection of 
Chlamydia infection by serology were either genus- 
specific complement fixation or species-specific micro- 
immunofluorescence. Most of the studies using the 
latter technique reported a higher incidence of C. 
pneumoniae (Almirall et al [5] 15%, Blasi et a1 [12] 13%, 
Bates et a1 [lo] 8%, Fang et a1 [7] 6%, Christiansen et 
a1 [13] 2%), with the exception of Ortqvist et a1 [8], 
who did not find any cases. Those using complement 
fixation reported an incidence between 0% and 3% 
only. The sensitivity of the complement-fixation test 
has been shown to be low, particularly in the elderly, 
where most infections are reinfections without IgM or 
complement-fixing antibodies being formed [I 51. 
Further differences may occur within the group for 
which microimniunofluorescence is used, due to 
different antigen preparations, for which sensitivity and 
specificity may vary. Most studies used the antigen 
preparations from either the Washington Research 
Foundation or the Institute of Ophthalmology in 
London, although several were unspecified. There have 
been several publications questioning the specificity of 
this test. Ozanne and Lefebvre [16] reported a speci- 
ficity of only 50% for IgM and 63% for IgG in a 
population with respiratory tract infection, and in a 
healthy population close correlation was found between 
C. pneumoniae and C .  trachomatis seropositivity, indica- 
ting a lack of specificity within the genus [17]. False- 
positive IgM results have also been reported in patients 
with rheumatoid factor, necessitating preabsorption of 
sera [ 181. Finally, the timing of the convalescent serum 
is of importance, as the microimmunofluorescence test 
may not show an increase in titer until 4 weeks after 
infection. Ekman et a1 [15] demonstrated that of those 
with a positive test, only 50% were positive at 2 weeks. 
Thus, those studies in which the follow-up sera were 
obtained early may have significantly underdiagnosed 
C .  pneumoniae infection. 
Mycoplasma pneumoniae 
Seroconversion, a fourfold rise in titer or a single high 
titer using complement fixation (CF) were the criteria 
used by most of the studies for diagnosing infection by 
this organism. None used any cultural technique or 
more advanced methods such as direct antigen 
detection by monoclonal antibodies, hybridization or 
DNA amplification. There are many problems with the 
use of the CF test as the sole diagnostic method. It is 
not as sensitive as IgM/IgA/IgG detection by immuno- 
fluorescence, titers remain elevated for many months, 
and there is questionable specificity of the lipid antigen 
preparation [19,20]. In addition, with reinfection, IgM 
antibodies may not be formed, reducing the sensitivity 
of the CF  test. The low frequency of Mycoplasma 
infection in many studies may be a reflection of the 
inadequacy of the testing methods. 
Legionella spp.  
There was a variation in the number of serogroups 
included in the testing for L. pneumophila. Most tested 
for groups 1 to 6 but the one study [4] in which no 
Legionella was found tested only for serogroup 1. 
Another variation was the inclusion of other species, 
some testing for L. micdadei and one [I31 for L. 
longbeachae. As with C. pneumoniae, the serologic res- 
ponse may take up to a month. Therefore, those studies 
in which the second sera were obtained at only 2 weeks 
would have underdiagnosed this infection. 
CLINICAL ASPECTS 
Epidemiologic studies give, at best, an indication of the 
range of pathogens that can cause CAP. The prediction 
of an infecting organism based on the frequency of 
isolation has been shown from the above studies to be 
unreliable. When an individual patient presents with 
pneumonia, a decision must be made regarding initial 
antibiotic therapy. In the past this was very much 
determined by the clinical presentation of the patient 
and chest radiographic appearances. All lobar pneu- 
monia was assumed to be pneumococcal unless proven 
otherwise, and any diffuse pulmonary disease due to 
one of the misnamed 'atypical' organisms such as Myco- 
plasma, Chlamydia or Legionella. Current knowledge has 
forced a re-evaluation of this approach and it is 
recognized that other factors must be considered in 
deciding on any empirical antibiotic regimen. 
Patient age 
Patient age may influence therapeutic decisions in two 
ways. First, those over 60 years have a significantly 
higher mortality. Second, there is an association of 
particular pathogens with different age groups. The age 
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Figure 1 Incidence of major pathogens with age [13] 
distribution of the patients for three of the major 
pathogens are shown in Figure 1 [13]. As can be seen, 
S. pneumoniae, although most common in the elderly, 
occurred across all age groups. This distribution was 
similar for H. inzuenzae. Mycoplasma infections, how- 
ever, occurred much more commonly in the 20 to 40 
age group. The age distribution for this latter organism 
was defined more clearly during an epidemic in 
Scotland, in which 594 patients had confirmed Myco- 
plasma infection [21] and in a study [22] on a prepaid 
medical group in Seattle (Figure 2). C. pneumoniae was 
originally described in a college student population 
[23] and hence initially was thought to be somewhat 
similar in epidemiology to M ~ C O ~ ~ A S ~ A  pneumoniae.
However, it is increasingly being diagnoscd in the 
elderly, in whom a more severe form of the illness may 
be seen, and in the epidemiologic studies that 
specifically looked for C .  pneumoniae there was no 
difference in the mean age of all patients admitted with 
pneumonia and those with C. pneumoniae. What is also 
apparent from these studies is that the organism was 
often present in conjunction with another cause of 
pneumonia. This may reflect some serologic cross- 
reactivity, or infection with one of these organisms 
predisposing to infection by the other. 
Figure 2 Mycoplasma pneumoniae - incidence with age. 
Underlying disease 
Pre-existing diseases such as chronic obstructive pul- 
monary disease, diabetes mellitus, alcoholism, renal 
disease, altered mental state, smoking and a preceding 
influenza infection influence the type of pathogen 
responsible for pneumonia and also increase the 
mortality rate. With chronic obstructive pulmonary 
disease, the airways are colonized with organisms such 
as S. pneumoniae, H.  influenzae and Moraxella catarrhalis, 
making infection with these organisms more likely. 
Similarly, the airways disease induced by smoking pre- 
disposes to these same organisms. Stapkylococcus aureus 
infections are well described as causing a very severe 
pneumonia following an influenza infection. 
Local epidemics and endemic organism 
Mycopl~sma pneumoniae has been shown by some 
workers to follow a 4-year epidemic cycle. Local 
knowledge, therefore, on any epidemic situation can be 
helpful. Similarly, Legionella pneumophila occurs both 
sporadically and in association with a single source 
causing an epidemic. Other Legionella species such as L. 
longbeadzae are less clustered, although they may occur 
in association with contact with contaminated potting 
soil. Some organisms are endemic to a particular region 
and may therefore cause a relatively disproportionate 
number of cases of pneumonia when compared to 
other organisms. 
Clinical presentation 
The symptoms and signs on presentation in the past 
were thought to constitute a good indication of the 
likely pathogen causing pneumonia. An illness of 
sudden onset, productive cough with blood-stained 
sputum, fever, signs of lobar consolidation and an 
elevated white blood cell count were considered almost 
pathognomonic of a S. pneumoniae infection. Con- 
versely, an illness with slower onset, non-productive 
cough, low-grade fever and extrapulmonary symptoms 
is often described for Mycoplasma and Chlamydia 
infections. However, while this may be true for a large 
number of patients, there is much overlap. In a study 
by Farr et a1 [24] these parameters were used to predict 
the microbial etiology on the clinical presentations of 
patients with pneumonia. The results, using discrimi- 
nant function analysis, showed a correct prediction in 
only 42% of cases. Fang et a1 171 also concluded after 
statistical analysis that there was no significant difference 
in presentation between the various organisms. In 
particular, patients with Legionella infections did not 
have any more significant abdominal pain, vomiting, 
neurologic changes, abnormal liver function tests or 
hyponatremia than other cases. The only distinctive 
feature found was for C .  pneumoniae infections; a third 
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of the patients had mental state changes. Similarly, 
radiographic appearances have been analyzed in order 
to determine if the etiologic agent can be predicted by 
particular X-ray appearances. Tew et a1 [25] examined 
the radiographs from 31 patients and could not 
accurately discriminate between bacterial (including 
Mycoplasmu) and viral infections. MacFarlane et a1 [26] 
studied 196 patients and could not reliably separate 
pneumonia due to S. pneumoniae, L. pneumoniae, Myco- 
plasma pneumoniae and C. psittaci. Lastly, Chan et a1 [27] 
evaluated the radiographs from 90 patients and, 
interestingly, could not discriminate between S. pneu- 
moniae, H. injuenzae, Staphylococcus aureus and the acute 
presentation of Mycobacterium tuberculosis. 
Severity of illness 
Patients with pneumonia can be categorized by the 
severity of illness, i.e. mild, moderate or severe. The 
pneumonia is either sufficiently mild to be managed 
within the community or the patient requires hos- 
pitalization. The clinical features of these latter patients 
have been defined [28]. Other studies have analyzed 
those factors that predict a high mortality and therefore 
those patients requiring intensive care and broad- 
spectrum antibiotics of high potency. The major 
predictors of death from pneumonia include: age > 60 
years, respiratory rate of 30/min or more, diastolic 
blood pressure < 60 mmHg, the development of 
impaired renal function, an altered mental state and 
radiographic extension of the pneumonia [29-321. 
SUMMARY 
Epidemiologic studies have provided us with the 
identity of the range of organisms that are likely to 
cause lower respiratory tract infection. What we lack is 
any means of reliably predicting which of these 
pathogens is responsible for the pneumonia in any 
particular patient on presentation. The clinical presen- 
tation and radiographic appearance are not sufficiently 
characteristic to provide the answer. Often, more than 
half the patients will have no identifiable cause despite 
thorough investigation. This may in part be due to the 
prior use of antibiotics or a lack ofsensitivity of current 
diagnostic techniques. The existence of as yet un- 
discovered organisms should also not be discounted. It 
is possible that in the future more direct antigen- 
detection techniques will be available. Multiplex 
polymerase chain reaction (PCK) may be developed, 
but, given that many of the organisms colonize the 
oropharynx, the high sensitivity of this method may be 
a problem. Culture takes some time to provide an 
answer and is therefore not of relevance when 
considering empirical therapy. It may be useful in 
moditjring treatment once an isolate is obtained and 
susceptibilities are available. However, it has been 
reported [33] that only 8% of patients with CAP had 
antibiotic therapy changed as a result of information 
obtained from microbial tests. Serology, at best, gives a 
retrospective diagnosis and therefore plays virtually no 
role in patient management. It is however, important 
for obtaining epidemiologic data and in identifying the 
presence of an epidemic. 
What then are the key factors that are important in 
determining the empirical regimen for a patient 
presenting with pneumonia? If mortality is to be 
reduced, those patients at  greatest risk of severe illness 
must be identified. Factors such as age, underlying 
disease and severity a t  presentation are probably the 
most discriminating. The Canadian Community Ac- 
quired Pneumonia Consensus Conference Group [34] 
and the American Thoracic Society [35] have made 
recommendations for specific antibiotic regimens to 
cover a wide range of possible infecting organisms on 
the basis of these three factors. It will be interesting to 
establish over time whether this approach has a 
significant impact on mortality from this very common 
disease. 
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